Medication info
Biprolidine 5/80 mg

Biprolidine 5/80 mg

Prescription medicationTabletOral
Ingredient · strength
Valsartan›80mg / 1 tabletAmlodipine Besylate›6.935mg / 1 tablet
Manufacturer / importer
Ildong Pharmaceutical Co., Ltd.
Appearance
Dark yellow round film-coated tablets
Packaging
28 tablets/box [(14 tablets/PTP)×2]
Approval status
Active

MFDS item code 201308434 · Approved 2013.07.29 · Insurance code 642904850

Summary

Main use
Treatment of essential hypertension not controlled with monotherapy
Who takes it
Adults · Children
Adult dose
The recommended dose is 1 tablet once daily, taken with water, regardless of meals. It is recommended that the tablet be taken at the same time each day, if possible (e.g., in the morning). Before starting this medicine, it is recommended that the dose be adjusted using the individual components (amlodipine or valsartan). However, if blood pressure is not adequately controlled with monotherapy using either individual component, switching directly to this medicine may be considered as follows: ㆍ5/80 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or valsartan 80 mg monotherapy. ㆍ5/160 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or valsartan 160 mg monotherapy. ㆍ10/160 mg: For patients whose blood pressure is not adequately controlled with amlodipine 10 mg or valsartan 160 mg monotherapy, or with 5/160 mg. Patients taking valsartan and amlodipine concomitantly may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience. Patients with renal impairment: No dosage adjustment is required in patients with mild or moderate renal impairment (creatinine clearance 10mL/min or higher). However, this medicine should not be administered to patients with severe renal impairment (creatinine clearance less than 10mL/min) or patients on dialysis. Monitoring of potassium levels and creatinine is recommended in patients with moderate renal impairment. Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, the daily dose of valsartan should not exceed 80mg. This medicine should not be administered to patients with severe hepatic impairment, biliary cirrhosis, biliary obstruction, or cholestasis. Patients 65 years of age or older: Caution should be exercised when increasing the dose.
Child dose
The safety and efficacy of this medicine have not been established in pediatric patients under 18 years of age; therefore, its use is not recommended.

Ingredients

Manufacturer
Ildong Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of essential hypertension not controlled with monotherapy

  • Essential hypertension
View approved original text

This medication helps manage blood pressure more effectively when blood pressure is not sufficiently controlled with either amlodipine or valsartan alone in patients with essential hypertension. It contributes to stabilizing blood pressure, thereby reducing the risk of cardiovascular diseases. This medication is used to improve blood pressure through a combined action.

How to take

Adult dose

The recommended dose is 1 tablet once daily, taken with water, regardless of meals. It is recommended that the tablet be taken at the same time each day, if possible (e.g., in the morning). Before starting this medicine, it is recommended that the dose be adjusted using the individual components (amlodipine or valsartan). However, if blood pressure is not adequately controlled with monotherapy using either individual component, switching directly to this medicine may be considered as follows: ㆍ5/80 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or valsartan 80 mg monotherapy. ㆍ5/160 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or valsartan 160 mg monotherapy. ㆍ10/160 mg: For patients whose blood pressure is not adequately controlled with amlodipine 10 mg or valsartan 160 mg monotherapy, or with 5/160 mg. Patients taking valsartan and amlodipine concomitantly may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience. Patients with renal impairment: No dosage adjustment is required in patients with mild or moderate renal impairment (creatinine clearance 10mL/min or higher). However, this medicine should not be administered to patients with severe renal impairment (creatinine clearance less than 10mL/min) or patients on dialysis. Monitoring of potassium levels and creatinine is recommended in patients with moderate renal impairment. Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, the daily dose of valsartan should not exceed 80mg. This medicine should not be administered to patients with severe hepatic impairment, biliary cirrhosis, biliary obstruction, or cholestasis. Patients 65 years of age or older: Caution should be exercised when increasing the dose.

Child dose

The safety and efficacy of this medicine have not been established in pediatric patients under 18 years of age; therefore, its use is not recommended.

Precautions

This medication may cause serious harm to the fetus and newborn if taken during pregnancy in the second or third trimester; therefore, if pregnancy is confirmed, it should be discontinued immediately. This medication should not be administered to individuals allergic to the active ingredients or similar drug classes, pregnant or potentially pregnant women, and breastfeeding women. It should also be avoided in patients with severely impaired kidney or liver function, certain heart diseases, or a history of angioedema. Patients with a deficiency of sodium or fluids in their body may experience low blood pressure, so conditions should be managed prior to administration, and blood pressure should be monitored closely during treatment. Patients with high potassium levels should be cautious when taking this medication with drugs that can increase potassium, and blood potassium levels should be checked regularly. Patients with problems in renal vasculature or those who have undergone kidney transplants may experience worsening kidney function when taking this medication, requiring careful monitoring. If symptoms of angioedema appear during treatment, the medication should be stopped immediately, and it should not be re-administered. Patients with heart failure or post-myocardial infarction should have regular kidney function tests during treatment and be aware of the potential for adverse effects, such as pulmonary edema. Patients with acute myocardial infarction or certain heart valve diseases should also exercise caution while taking this medication. It is recommended not to take this medication in combination with other renin-angiotensin-aldosterone system drugs, and dosage should be adjusted in patients with liver impairment. Caution is needed when driving or operating machinery as dizziness or fatigue may occur. Overdosage may lead to low blood pressure or cardiac-related adverse effects, thus strict adherence to the dosages is essential, and any abnormal symptoms should be reported to healthcare professionals immediately. This medication has not been sufficiently validated for safety and efficacy in children and is not recommended for them. Elderly patients may be given the same dosage as adults, but consultation with healthcare providers is advised depending on individual conditions. Regular monitoring of blood pressure, kidney function, electrolyte levels, etc., during treatment is crucial. Particularly, this medication contains both a calcium channel blocker and an angiotensin receptor blocker, necessitating attention to the side effects and interactions characteristic to both drugs.

Side effects

nasopharyngitis, influenza, hypersensitivity, visual impairment, anxiety, headache, dizziness, drowsiness, positional dizziness, sensory disturbance, vertigo, tinnitus, tachycardia, palpitations, fainting, orthostatic hypotension, hypotension, cough, pharyngeal and laryngeal pain, diarrhea, nausea, abdominal pain, constipation, dry mouth, rash, erythema, hyperhidrosis, itching, joint swelling, lumbago, arthritis, muscle cramps, weakness, polyuria, nocturia, erectile dysfunction, edema, angioedema, facial edema, peripheral edema, fatigue, flushing, asthenia, facial flushing, decreased hemoglobin, decreased hematocrit, neutropenia, thrombocytopenia, hypersensitivity including serum sickness, increased serum potassium, vasculitis, elevated liver function tests, angioedema, myalgia, renal failure, kidney damage, elevated serum creatinine, insomnia, decreased libido, pharyngitis, rhinitis, sinusitis, upper respiratory tract infection, viral infection, diplopia, thrombocytopenic purpura, leukopenia, allergic reaction, hyperglycemia, insomnia, mood changes, tremors, sensory loss, taste disturbances, peripheral neuropathy, hypertonicity, arrhythmia, bradycardia, atrial fibrillation, ventricular tachycardia, myocardial infarction, vasculitis, dyspnea, rhinitis, vomiting, dyspepsia, pancreatitis, gastritis, gum hyperplasia, hepatitis, jaundice, alopecia, purpura, skin depigmentation, photosensitivity reaction, angioedema, urticaria, erythema multiforme, Stevens-Johnson syndrome, myalgia, urination disorder, nocturnal enuresis, gynecomastia, pain, malaise, chest pain, weight loss, weight gain, elevated liver enzymes, chest discomfort, abdominal discomfort, gastroesophageal reflux disease, neck pain, hypercholesterolemia, hypoglycemia, neuroexcitability, Stevens-Johnson syndrome, chest pain, weight gain, arthralgia, skeletal pain, rhabdomyolysis, gingival hyperplasia, gastritis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a sealed container to protect it from air and moisture. It is advisable to maintain a storage temperature between 1 to 30 degrees Celsius at room temperature. This will help maintain the efficacy and safety of the medication over an extended period.

Appearance and packaging

Appearance

Dark yellow round film-coated tablets

Package unit

28 tablets/box [(14 tablets/PTP)×2]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.